Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 Patients
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 534
- 试验地点
- 1
- 主要终点
- presence of SARS-CoV-2 genome in tears
研究概览
简要总结
To evaluate the prevalence of SARS-CoV-2 genome in patients with asymptomatic and moderately symptomatic COVID19.
详细描述
Patients attending to the COVID19 screening facility of Paris South University hospital and willing to participate to the study will have both nasopharyngeal and conjunctival swab for SARS-CV-2 genome detection using PCR. The project will evaluate the prevalence of positive conjunctival swabs in patients with positive nasopharyngeal swab. These results will be corelated to symptoms of disease assessed with a standardized questionnaire.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients receiving diagnostic nasopharyngeal PCR for COVID-19 as part of the usual care
- •Information and signature of consent
- •Affiliated with a social security scheme or entitled
排除标准
- •Refusal to participate in the study
- •Eye surgery less than 3 months old
- •Unable to give informed consent
- •No coverage through the health insurance system
- •Patient under judicial protection
- •Patient on AME
研究组 & 干预措施
Patients attending to the COVID19 screening facility
Patients will have both nasopharyngeal and conjunctival swab for SARS-CV-2 genome detection using PCR. Study will evaluate the prevalence of positive conjunctival swabs in patients with positive nasopharyngeal swab. These results will be corelated to symptoms of disease assessed with a stan
干预措施: conjunctival swab (Diagnostic Test)
结局指标
主要结局
presence of SARS-CoV-2 genome in tears
时间窗: at the end of the study, an average of 1 year
Prevalence of SARS-CoV-2 genome in tears
次要结局
- presence of systemic symptoms evaluated at the time of making an appointment by a systematic standardized interrogation(at the end of the study, an average of 1 year)
- assessement of viral load levels(at the end of the study, an average of 1 year)